Salemonline Journal

Bronchopulmonary Dysplasia Pipeline Insight 2021 by DelveInsight

 Breaking News
  • No posts were found

Bronchopulmonary Dysplasia Pipeline Insight 2021 by DelveInsight

April 15
00:24 2021
Bronchopulmonary Dysplasia Pipeline Insight 2021 by DelveInsight

Bronchopulmonary Dysplasia Pipeline” report has been added to DelveInsight

 

Bronchopulmonary Dysplasia Pipeline analysis across different stages of development (Phase III & Phase II), different emerging trends and comparative analysis of Bronchopulmonary Dysplasia pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities

 

Download free sample copy here- https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight

 

Bronchopulmonary Dysplasia Overview

Bronchopulmonary Dysplasia (BPD) is defined as the need for increased oxygen in infants: 28 d or at discharge (whichever comes first). It applied the clinical criteria from both 28 days of oxygen need and an assessment of respiratory support at 36 weeks’ post menstrual age (PMA).

 

Bronchopulmonary Dysplasia Pipeline Report

The definition of BPD has evolved throughout the years. The new BPD includes total duration of oxygen supplementation, positive pressure requirements, and gestational age, in addition to oxygen dependency at 36 weeks. The definition allows the severity of the disease to be classified into mild, moderate and severe form, by oxygen dependency and respiratory support at 36 weeks’ PMA.

 

Bronchopulmonary Dysplasia Pipeline Insights

With the ongoing improvements in neonatal intensive care, both the pathogenesis and histology of BPD has changed, along with reporting in preterm infants. The factors contributing to this disease’s entity can be separated into pre- and post-natal causes such as genetic susceptibility, the immaturity of the surfactant homeostasis, intrauterine and perinatal infections, and lung growth restriction, mechanical ventilation and oxygen therapy induce a pulmonary inflammatory response.

 

Bronchopulmonary Dysplasia Key Players

  • Medipost
  • Windtree Therapeutics
  • Therabron Therapeutics
  • Shire/ Takeda

 

Bronchopulmonary Dysplasia Drugs

  • PNEUMOSTEM
  • AEROSURF
  • CG100
  • SHP607

 

Bronchopulmonary Dysplasia Report Highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Bronchopulmonary Dysplasia.   
  • In the coming years, the Bronchopulmonary Dysplasia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Bronchopulmonary Dysplasia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the Bronchopulmonary Dysplasia treatment market. Several potential therapies for Bronchopulmonary Dysplasia are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Bronchopulmonary Dysplasia market size in the coming years. 
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Bronchopulmonary Dysplasia) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 

Following is the TOC of Bronchopulmonary Dysplasia pipeline report

1. Report Introduction

2. Bronchopulmonary Dysplasia 

3. Bronchopulmonary Dysplasia Current Treatment Patterns

4. Bronchopulmonary Dysplasia – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Bronchopulmonary Dysplasia Late Stage Products (Phase-III)

7. Bronchopulmonary Dysplasia Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Bronchopulmonary Dysplasia Discontinued Products

13. Bronchopulmonary Dysplasia Product Profiles

14. Bronchopulmonary Dysplasia Key Companies

15. Bronchopulmonary Dysplasia Key Products

16. Dormant and Discontinued Products

17. Bronchopulmonary Dysplasia Unmet Needs

18. Bronchopulmonary Dysplasia Future Perspectives

19. Bronchopulmonary Dysplasia Analyst Review  

20. Appendix

21. Report Methodology

 

What are the key questions of this report?

 

  • What are the current options for Bronchopulmonary Dysplasia treatment?
  • How many companies are developing therapies for the treatment of Bronchopulmonary Dysplasia?
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of Bronchopulmonary Dysplasia?
  • How many Bronchopulmonary Dysplasia emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Bronchopulmonary Dysplasia?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Bronchopulmonary Dysplasia market?
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Bronchopulmonary Dysplasia? 
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Bronchopulmonary Dysplasia therapies?
  • What are the clinical studies going on for Bronchopulmonary Dysplasia and their status?
  • What are the results of the clinical studies and their safety and efficacy?
  • What are the key designations that have been granted for the emerging therapies for Bronchopulmonary Dysplasia?
  • How many patents are granted and pending for the emerging therapies for the treatment of Bronchopulmonary Dysplasia?

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: www.delveinsight.com/

Related Articles